Disease progression on endocrine therapy in advanced setting
Showing 1 - 25 of >10,000
A NIS of Alpelisib in Combination With Fulvestrant in
Not yet recruiting
- Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
- Alpelisib
- Fulvestrant
- (no location specified)
Aug 9, 2022
Tumor, Breast, Congenital, Familial and Genetic Disorders Trial in Netherlands (Alpelisib 150 MG Oral Tablet [Piqray],
Recruiting
- Neoplasm, Breast
- Congenital, Familial and Genetic Disorders
- Alpelisib 150 MG Oral Tablet [Piqray]
- Fulvestrant
-
Almelo, Netherlands
- +15 more
Jan 11, 2023
Solid Tumor, Adult Trial (EOC202, albumin-bound paclitaxel)
Not yet recruiting
- Solid Tumor, Adult
- EOC202
- albumin-bound paclitaxel
- (no location specified)
Apr 7, 2022
Metastatic Breast Cancer Trial in Shanghai (Trastuzumab, pyrotinib, Dalpiciclib)
Not yet recruiting
- Metastatic Breast Cancer
- Trastuzumab
- +3 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center Shanghai, China, 200032
Oct 11, 2022
Metastatic Breast Cancer Trial in Frankfurt am Main (Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel,
Recruiting
- Metastatic Breast Cancer
- Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)
-
Frankfurt am Main, GermanyAgaplesion Markus Krankenhaus - Klinik für Gynäkologie und Gebur
Feb 22, 2022
Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine Trial in Nanjing (Trastuzumab Emtansine (T-DM1))
Recruiting
- Advanced Breast Cancer
- +2 more
- Trastuzumab Emtansine (T-DM1)
-
Nanjing, Jiangsu, ChinaJiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Nov 5, 2023
HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer Trial in Canada (Endocrine therapy may include one of the following
Active, not recruiting
- HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer
- Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant
- Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy
-
Calgary, Alberta, Canada
- +24 more
Sep 12, 2022
Advanced Solid Tumor, Breast Cancer Trial in Columbus, San Antonio, West Valley City (CFI-402257, Fulvestrant)
Recruiting
- Advanced Solid Tumor
- Breast Cancer
-
Columbus, Ohio
- +2 more
Jul 26, 2022
First-line Palbociclib and Endocrine Therapy for HR+/HER2-
Recruiting
- Breast Neoplasms
- Palbociclib + endocrine therapy
-
Ansbach, Germany
- +106 more
Feb 25, 2022
Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2
Recruiting
- Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
-
Duarte, California
- +12 more
Jul 6, 2022
Metastatic Breast Cancer Trial in Springfield, Rochester, Lebanon (17B-estradiol, Letrozole, Anastrozole)
Active, not recruiting
- Metastatic Breast Cancer
- 17B-estradiol
- +3 more
-
Springfield, Massachusetts
- +2 more
Nov 1, 2022
Pancreatic Adenocarcinoma Trial in Philadelphia (Niraparib + Nivolumab, Niraparib + Ipilimumab)
Active, not recruiting
- Pancreatic Adenocarcinoma
- Niraparib + Nivolumab
- Niraparib + Ipilimumab
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania, Abramson Cancer Center
Mar 23, 2022
Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult Trial (Patritumab deruxtecan)
Not yet recruiting
- Metastatic Breast Cancer
- +2 more
- Patritumab deruxtecan
- (no location specified)
May 9, 2023
Breast Cancer Trial in Athens
Recruiting
- Breast Cancer
-
Athens, GreeceHellenic Oncology Cooperative Group
May 13, 2022
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast
Terminated
- Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
-
Phoenix, Arizona
- +39 more
Jun 21, 2022
Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Tampa
Recruiting
- Lung Non-Small Cell Carcinoma
- +4 more
- Carboplatin
- +2 more
-
Tampa, FloridaMoffitt Cancer Center
Aug 16, 2022
Locally Advanced or Metastatic Breast Cancer Trial in Guangzhou (SPH4336 Tablets, SPH4336 Tablets Placebo)
Not yet recruiting
- Locally Advanced or Metastatic Breast Cancer
- SPH4336 Tablets
- SPH4336 Tablets Placebo
-
Guangzhou, Guangdong, ChinaAffiliated Cancer Hospital, Sun Yat-sen University
May 8, 2023
Breast Cancer, Ovarian Cancer, Liposarcoma Trial (PF-07224826, Fulvestrant)
Not yet recruiting
- Breast Cancer
- +5 more
- PF-07224826
- Fulvestrant
- (no location specified)
Jun 7, 2023
Breast Cancer Trial in Wuhan (Adebrelimab, dalpiciclib)
Recruiting
- Breast Cancer
-
Wuhan, Hubei, ChinaTongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 20, 2023
Advanced Breast Cancer Trial in Beijing (The combination of Dalpiciclib with physician-selected endocrine therapy, Chemotherapy
Recruiting
- Advanced Breast Cancer
- The combination of Dalpiciclib with physician-selected endocrine therapy
- Chemotherapy selected by the physician
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
May 22, 2023
CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent
Not yet recruiting
- Breast Cancer
- +3 more
- Different treatment regimens following progression on CDK4/6 inhibitors.
- (no location specified)
Sep 5, 2023
Hepatocellular Carcinoma Trial in Dallas (Pembrolizumab, Bavituximab)
Recruiting
- Hepatocellular Carcinoma
-
Dallas, TexasUniversity of Texas Southwestern Medical Center
Apr 27, 2022